Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 12, 2023

Association of PD-L1 Expression With Efficacy of Alectinib in Patients With Advanced NSCLC With ALK Fusion

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
Lung Cancer 2023 Jul 01;181(xx)107233, Y Pan, X Liu, W Zhang, W Wang, H Wang, L Luo, K Jia, C Shao, S Mao, T Qiu, J Ni, J Yu, L Wang, B Chen, A Xiong, G Gao, X Chen, F Wu, C Zhou, C Wu, S Ren

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading